LUME-Lung 1: PFS primary endpoint
met
Independent central review in all patients (N=1134)
Reck M, et al.
Lancet Oncol
2014;15:143–155.
100
80
60
40
20
Probability of PFS (%)
0
2 4 6 8 10 12 14 16 18
Time (months)
0
No. at risk
Nintedanib 565 295 155 57 19 4 3 1 0
Placebo 569 250 116 43 21 2 1 0 0
Nintedanib +
docetaxel
Placebo +
docetaxel
Median PFS (months)
3.4
2.7
HR =
0.79
(95% CI: 0.68–0.92);
p=0.0019
Independent central review
